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NLRP3 is a receptor important for host responses
to infection, yet is also known to contribute to devas-
tating diseases such as Alzheimer’s disease, dia-
betes, atherosclerosis, and others, making inhibitors
forNLRP3 sought after. Oneof the inhibitors currently
in use is 2-aminoethoxy diphenylborinate (2APB).
Unfortunately, in addition to inhibiting NLRP3, 2APB
also displays non-selective effects on cellular Ca2+
homeostasis. Here, we use 2APB as a chemical scaf-
fold to build a series of inhibitors, the NBC series,
which inhibit the NLRP3 inflammasome in vitro and
in vivo without affecting Ca2+ homeostasis. The core
chemical insight of this work is that the oxazaborine
ring is a critical feature of the NBC series, and the
main biological insight the use of NBC inhibitors led
to was that NLRP3 inflammasome activation was
independent of Ca2+. TheNBCcompounds represent
useful tools to dissect NLRP3 function, and may lead
to oxazaborine ring-containing therapeutics.
INTRODUCTION
Inflammation, which contributes to almost all known non-in-
fectious diseases, is triggered by infection or injury sensed by
pattern recognition receptors (PRRs) on inflammatory cells.
Soluble PRRs have received particular attention due to their
ability to form molecular complexes known as inflammasomes,
which facilitate the release of inflammatory cytokines such as
interleukin-1b (IL-1b), an important aspect of the inflammatory
response. Inflammasomes are formed following the activation
of cytosolic PRRs, of which the NOD-like receptor (NLR) family,
pyrin domain-containing protein 3 (NLRP3), is the best charac-
terized. The NLRP3 inflammasome is formed when NLRP3,
described mainly in macrophages and monocytes, senses theCell Chemical Biology 24, 1321–1335, Novem
This is an open access article undpresence of pathogen-associated molecular patterns (PAMPs)
or damage-associated molecular patterns (DAMPs). Upon its
activation, NLRP3 binds to the adapter protein ASC (apoptosis-
associated speck-like protein containing a caspase activation
and recruitment domain), which in turn recruits pro-caspase-1
to form an inflammasome complex. This results in the activation
of caspase-1, which in turn cleaves pro-forms of the pro-inflam-
matory cytokines IL-1b and IL-18, causing their activation and
facilitating their release from the cell (Latz et al., 2013).
NLRP3-dependent cytokine release is implicated in the devel-
opment of several important diseases (McGettrick and O’Neill,
2013; Heneka et al., 2015) and may represent a pharmacological
target for the treatment of inflammatory disease (Coll et al.,
2015; Daniels et al., 2016). Signaling mechanisms regulating
the activation of NLRP3 remain to be fully characterized. One
signaling mechanism proposed to regulate the activation of
the NLRP3 inflammasome is an increase in intracellular cal-
cium ([Ca2+]i) (Horng, 2014). Many reports suggesting an involve-
ment of Ca2+ in inflammasome activation have used the Ca2+-
signaling inhibitor 2-aminoethoxy diphenylborinate (2APB, 1)
(Lee et al., 2012; Murakami et al., 2012; Compan et al., 2012;
Rossol et al., 2012).
2APB is a cell-permeable small-molecule inhibitor of Ca2+
homeostasis with multiple targets including inositol 1,4,5-tri-
sphosphate (InsP3)-dependent Ca
2+ release, store-operated
Ca2+ entry, and potentially also Ca2+ pumps and mitochondria,
where effects are described as use-dependent and poorly
reversible (Peppiatt et al., 2003). 2APB is also a poorly selective
TRP (transient receptor potential) channel blocker (Schaefer,
2014). However, recent evidence suggests that the effects of
2APB on inflammasome activation may be independent of an
effect on Ca2+ (Katsnelson et al., 2015). The utility of 2APB as
an inhibitor of NLRP3, however, is limited by its non-selective
effects on cellular Ca2+ homeostasis. Our aim was to develop
new and potent inflammasome inhibitors based on the scaffold
of 2APB but with reduced non-specific effects on Ca2+ homeo-
stasis. We describe NBC6 (and its analogs) as completely new
and potent inhibitors of the NLRP3 inflammasome that act inde-
pendently of Ca2+.ber 16, 2017 ª 2017 The Authors. Published by Elsevier Ltd. 1321
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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acyclic cyclic
2-APB (1) DPBA (2) DPH (3) DPTTF (4) PHENY(5)
NCI1 (6) NCI2 (7) NCI3 (8) NCI4 (9) NCI5 (10) NCI6 (11) NCI7 (12)
Figure 1. Establishing the Importance of Boron in 2APB for NLRP3 Inflammasome Inhibition
(A–G) Mouse peritoneal macrophages were primed with bacterial endotoxin (lipopolysaccharide [LPS], 1 mg mL1, 2 hr) and then stimulated with vehicle (0.5%
DMSO) or 2APB (75 mM) before stimulation with ATP (5 mM, 20 min) (A), nigericin (20 mM, 15 min) (B), sphingosine (20 mM, 1 hr) (C), monosodium urate crystals
(MSU; 250 mg mL1, 1 hr) (D), calcium pyrophosphate dehydrate crystals (CPPD; 250 mg mL1, 1 hr) (E), or aluminum hydroxide (Alum; 250 mg mL1, 1 hr) (F). The
half-maximal inhibitory concentration (IC50) for the effects of 2APB on IL-1b release induced by ATP was established using a 3-parameter logistical sigmoidal
model (G).
(legend continued on next page)
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RESULTS
Inhibitory Effects of 2APB Require Boron
To establish that 2APB was a robust NLRP3 inflammasome
inhibitor, mouse peritoneal macrophages were primed with
LPS and then stimulated with a range of NLRP3 inflamma-
some-activating DAMPs. After LPS cells received pre-treatment
with 2APB, which was then present for the duration of DAMP
stimulation, 2APB inhibited the release of IL-1b in response to
NLRP3 inflammasome activators ATP, nigericin, sphingosine,
monosodium urate crystals (MSU), calcium pyrophosphate dihy-
drate crystals (CPPD), or aluminum hydroxide (Alum) (Figures
1A–1F), consistent with previous work reporting 2APB as an in-
hibitor of the NLRP3 inflammasome (Lee et al., 2012; Murakami
et al., 2012; Compan et al., 2012; Rossol et al., 2012; Katsnelson
et al., 2015). To identify the pharmacophore of 2APB responsible
for the inhibition of IL-1b processing and release, we screened
a small library of 2APB analogs based on previously published
data investigating the pharmacophore responsible for the effects
of 2APB on store-operated Ca2+ entry (Dobrydneva and Black-
more, 2001). The acyclic structure of 2APB (1) is shown in Fig-
ure 1H, although in reality the ethanolamine coordinates to the
boron (B) atom to give a 5-membered ring cyclic structure.
Also shown is the analog diphenylborinic anhydride (DPBA, 2,
the dimerized dehydrated form of diphenylborinic acid), diphen-
hydramine (DPH, 3, a carbon analog of acyclic 2APB in which
there is no possibility of a closed ring form), 2,2-diphenyltetra-
hydrofuran (DPTTF, 4, which contains no B), and phenytoin
(PHENY, 5, which is similar to 2APB in that it has two phenyl
groups attached to a heterocyclic ring, but again does not
contain B). To test the effects of these analogs, we primed
mouse peritoneal macrophages with LPS and then pre-treated
with drug before stimulation with ATP. The drugwas also present
throughout the ATP stimulation. The effects of the drugs were
normalized to ATP-induced IL-1b release in the absence of any
drug (Figure 1I). The only analog to inhibit IL-1b release, in addi-
tion to 2APB, was the B-containing DPBA, with the other analogs
having no effect (Figure 1I). The half-maximal inhibitory concen-
tration (IC50) for the effects of 2APB on IL-1b release was 67 mM
(Figure 1G).
These data suggest the B atom is essential for the inhibitory
effects of 2APB on IL-1b release. To further test the requirement
for B, we used computational similarity searching using ROCS
(rapid overlay of chemical structures) (Grant et al., 1996) and
Tanimoto scoring (ShapeTanimoto and ColorTanimoto, for
shape and chemical similarity, respectively), to identify diverse
commercially available carbon analogs of 2APB for screening.
Several of the top ranked hits, selected on shape and pharmaco-
phore match (from a library of2 million non-B-containing com-
pounds from the ZINC ‘‘LeadsNow’’ database, zinc.docking.
org), were sourced via the repository of the NIH’s National Can-
cer Institute (NCI) Developmental Therapeutics Program and(H) Chemical structures of B-containing compounds 2APB (1) and DPBA (2) and
(I and J) Mouse peritoneal macrophages were primed as before and stimulated w
(5mM, 20min) (I). Mouse BMDMswere primed with LPS (1 mgmL1, 4 hr) and incu
before ATP stimulation (5 mM, 1 hr) (J).
In all cases supernatants were analyzed by ELISA. Data are presented as mean
*p < 0.05, **p < 0.01, ***p < 0.001, significant difference from 100% IL-1b releaswere screened against ATP-induced IL-1b release using primary
mouse bone marrow-derived macrophages (BMDMs). BMDMs
were primed with LPS and incubated with vehicle (0.5%
DMSO) ormolecules (NCI1–7, 6–12, Figure 1H) at 40 mM (to allow
any enhanced inhibitory activity to be observed) for 15 min
before ATP stimulation. The effects of the molecules were
normalized to ATP-induced IL-1b release (Figure 1J). None of
the carbon analogs were as effective as 2APB at this concentra-
tion, suggesting that the B atom is important for the inhibitory
activity of 2APB.
Refinement of the Structure-Activity Relationship
Given the apparent dependence on B, we screened a diverse
library of commercially available B-containing compounds
identified using SciFinder Scholar (called the BC series [for
boron compound]) that shared some features and properties
with 2APB (Figure S1). The BCmolecules were screened against
ATP-induced IL-1b release using primary mouse BMDMs as
described above. Cells were primed with LPS and incubated
with vehicle or molecules (BC1–24, Figure S1) before ATP stim-
ulation. The effects of the molecules on IL-1b release were
normalized to ATP-induced IL-1b release in the absence of any
inhibitor (Figure 2A). Through this approach we identified ana-
logs that were orders of magnitude more potent than 2APB
at inhibiting IL-1b release (e.g., 2APB, IC50 = 67 mM; BC7 (13),
IC50 = 1.2 mM; BC23 (14), IC50 = 2.3 mM; Figures 2B and 2C).
Our preliminary qualitative structure-activity relationship (SAR)
analysis identified the importance of the diarylborinic acid motif
and an oxazaborine ring, with conformationally restricted ana-
logs showing enhanced activity (Figure 2).
We then modified aspects of our lead BC molecules to
improve activity and solubility, in addition to identifying the phar-
macophore. Notably we modified the groups at each position of
the oxazaborine ring (Figures 3A–3D), with atom numbering of
the oxazaborine ring as shown in Figure 3E. A series of dioxa-,
oxaza-, and diazaborines (novel boron compounds [NBC]1–31)
based on the structures of BC7/23 were synthesized (for full
details see Methods S1). In brief, 1,3-dicarbonyls were reacted
with acetonitrile derivatives in the presence of a metal catalyst
(Zn(acac)2 or SnCl4) to yield acetylated enaminones, by adapting
previously reported methods (Veronese et al., 1986; Singh and
Lesher, 1978). These intermediates were readily deacetylated
by treating with K2CO3 (Veronese et al., 1986). Subsequent bor-
ylation of these enaminones using DPBA afforded the corre-
sponding oxazaborine NBC molecules using a method similar
to that previously described (Vasil’ev et al., 1992, Dorokhov
et al., 1995) (Figure 3A). The synthesis of oxazaborine NBC18
used similar chemistry, except that the starting material was
cyanoacetamide (Figure 3A). Dioxaborines were synthesized
by directly borylating 1,3-dicarbonyls (Bally et al., 1965) (Fig-
ure 3C). Reaction of BC23 with a range of alkyl amines yielded
diazaborines (Figure 3D) adapted from Vasil’ev et al. (2013).C-containing 2APB analogs (3–12).
ith vehicle (0.5% DMSO) or inhibitor (1–5, 75 mM) before stimulation with ATP
bated with vehicle (0.5%DMSO) ormolecules (NCI1–7, 6–12, 40 mM) for 15min
percentage of IL-1b release versus vehicle (DMSO) control + SEM (n = 3–9).
e (Holm-Sidak corrected one-sample t test).
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Figure 2. Identification of an Oxazaborine
Ring in an Improved Pharmacophore
Primary mouse BMDMs were primed with LPS
(1 mg mL1, 4 hr) and incubated with vehicle (0.5%
DMSO) or molecules (BC1–24, Figure S1) at 40 mM
for 15 min before ATP stimulation (5 mM, 1 hr).
The effects of the molecules on IL-1b release
were measured by ELISA and normalized to
ATP-induced IL-1b release in the absence of any
inhibitor (A). The chemical structures (i) and half-
maximal inhibitory concentration curves (IC50, ii)
for BC7 (B) and BC23 (C) are also presented using
a 3-parameter logistical sigmoidal model. Data are
presented as mean percentage of IL-1b release
versus vehicle (DMSO) control + SEM of at least 3
experiments. *p < 0.05, ***p < 0.001, significant
difference from 100% IL-1b release (Holm-Sidak
corrected one-sample t test). ###p < 0.001, signif-
icant improvement from 2APB treatment (Holm-
Sidak corrected post hoc comparison).Reaction of BC23 with ammonia did not give the expected
diazaborine product, and only the dechlorinated compound
containing a CHCl2 group (NBC29) was isolated. cLogP and
cLogS calculations were performed for BC7, BC23, NBC1–31,
and NBC-EPPS (Figure 3B), and demonstrate that a number of
potent NBC molecules (NBC6, 18, 24) have improved physico-
chemical properties compared with the original lead compounds
BC7 and BC23. Furthermore, an experimental LogS value for our
lead analogNBC6was found to be1.63 inMeOH (9.7mgmL1)
(data not shown). These data suggest that the NBC molecules
are sparingly soluble in aqueous solution.
To screen the NBC series we used the human monocytic
THP-1 cell line, since these cells would allow a higher throughput
compared with the primary cells used above. Cells were
primed with LPS and then treated with vehicle or NBC molecule
(NBC1–31) at 10 mM for 15min before activation of the inflamma-
some and IL-1b release with nigericin. The NBC molecule was1324 Cell Chemical Biology 24, 1321–1335, November 16, 2017present throughout nigericin stimulation.
The effects of the molecules on IL-1b
release were normalized to nigericin-
induced IL-1b release in the absence of
any inhibitor (Figure 3B). These data
showed some additional features of the
SAR (Figures 3B and 3E). Any substitu-
tion of the -CCl3 group at position 4 (Fig-
ure 3E) was detrimental to bioactivity: its
electronic character was important for
inhibition of IL-1b release, confirmed by
the substantially reduced activities of
the isosteric tBu (NBC28) and phenyl
(NBC23) analogs. A bis-oxazaborine
chelate (NBC8) was the only analog
lacking the CCl3 group that showed
good bioactivity, which may be attrib-
uted to the extra BPh2 group in the struc-
ture. Modifications of the oxazaborine
ring (O-B-N bonding) to a dioxaborine
(O-B-O) or diazaborine (N-B-N) ring struc-ture was also detrimental to bioactivity. An oxazaborine ring
structure was required, as the NBC6 enaminone intermediate
prior to borylation (NBC6i, without B) was inactive (not shown).
Modifications at the 5-position were generally tolerated, and
typically molecules containing a carbonyl group-containing moi-
ety showed enhanced bioactivity (Figures 3B and 3E). However,
the ester NBC-EPPS analog containing the buffer 4-(2-hydrox-
yethyl)-1-piperazinepropanesulfonic acid (EPPS) was less active
due to the substituent chain length either being too long or too
hydrophilic. Deacetylation at position 5 (e.g., NBC6 cf. NBC5)
leads to a loss in bioactivity (Figure 3E), so an acetyl group
was preferentially retained in this position. Changing the methyl
group at position 6modulated bioactivity (Figure 3E), with substi-
tution to the primary amide analog noticeably enhancing inflam-
masome inhibition (NBC6, 15) (Figure 3B). Changing the primary
amide to a secondary amide improved bioactivity as long as
the substituents were hydrophobic (alkyl or aromatic) and the
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Calc ConformationNBC19         (17)
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Figure 4. X-Ray Crystallography and
Computational Modeling of NBCs
(A and B) Crystal (X-ray) and predicted structure
(Calc) of NBC6 (15) (A) and NBC11 (16) (B), calcu-
lated at the M06-L/6-31G* level of theory. The ring
is boat-like in conformation (atom numbering
shown in A).
(C) Computed structure and Mulliken partial
charges on ring atoms of oxazaborine NBC19 (17).
(D) Computed structures of NBC27 (18) and
NBC30 (19) illustrating the planarity of the dia-
zaborine ring and Mulliken partial charges of
NBC27 and NBC30.
(E) Steric field arising from topomer CoMFA of 24
oxazaborine compounds, superimposed on
structures of (left) NBC19 and (right) NBC20.chain length of the substituent was not too short (R1 = Me,
NBC12) or too bulky (R1 = pyrene, NBC22). Full substitution of
the primary amide (NBC6) to the N,N-dimethyl tertiary amide de-
rivative (NBC11, 16) lost bioactivity, potentially due to a change
in chelation (see X-ray in Figures 4A and 4B). It was interesting to
note that secondary amide derivatives containing either phenyl
(NBC13) or cyclohexyl (NBC19, 17) substitutions are both active,
showing that the ring can be either unsaturated or saturated. InFigure 3. Refinement of the Structure-Activity Relationship
(A) Pathway for oxazaborine syntheses. The method for the synthesis of the oxazaborine compounds are d
SnCl4, dichloromethane/toluene, room temperature to 80
C, 3–16 hr; (ii) K2CO3(sat), EtOH, room temperature,
(iv) Cl3CCN, NaOAc, EtOH, room temperature, 16 hr (A).
(B–D) Table of oxazaborines synthesized with structure type (A, B or C) identified (B). Ad, adamantyl;
4-(2-hydroxyethyl)piperazine-1-propanesulfonic acid. Also shown in (B) to (D) is the percentage of inhibition of
cells with 10 mM inhibitor and the calculated cLogP and cLogS values for each compound. (C) Pathway for d
aNBC9 was isolated as a by-product during NBC5 synthesis. (D) Pathway for diazaborine synthesis. (v) RNH
(E) Summary of SAR analysis of NBCs.
(F) Half-maximal inhibitory concentration curve (IC50) for NBC6 (Fi) is presented using a 3-parameter logistic
*p < 0.05, **p < 0.01, ***p < 0.001, significant difference from 100% IL-1b release (Holm-Sidak corrected on
1326 Cell Chemical Biology 24, 1321–1335, November 16, 2017summary, an oxazaborine scaffold and a
CCl3 group on the 4-position was required
to inhibit IL-1b release (Figure 3E).
From the screen of NBC molecules,
NBC6 was most potent and more drug-
like compared with leads BC7/23, and
further analysis revealed increased po-
tency with an IC50 of 574 nM (Figure 3F).
X-Ray Crystallography and
Computational Modeling of NBCs
When borylating the enaminone inter-
mediates using DPBA, the oxazaborine
product could adopt a number of different
B chelate structures. For example, NBC6
and NBC11 could chelate to B through
the NH of the enamine and either the
amide or ketone C=O. To determine the
structures of the chelates in the solid
phase, crystals of NBC6 and NBC11
were grown in n-hexane/toluene (1:1)
and X-ray crystallographic analysis wasundertaken. The R factors obtained for NBC6 and NBC11 were
4.08% and 2.83%, respectively. The B atom lies out of the ring
plane in a boat-envelope conformation in both oxazaborine
structures, whereas the other atoms in the heterocycle are planar
and are involved in a p-electron conjugated system (Figure 4A)
as previously reported for other oxazaborines (Josefı´ka et al.,
2012; Mikyseka et al., 2017). NBC6 is chelated to B through
O/N chelation of the amide C=O and enamine NH (Figure 4A),escribed as types A, B, and C. (i) RCN, Zn(acac)2/
24 hr; (iii) DPBA, tetrahydrofuran (THF), 50C, 16 hr;
Cy, cyclohexyl; Pyr, pyrene; Py, pyridinyl; EPPS,
IL-1b release from LPS and nigericin-treated THP-1
ioxaborine syntheses. (iii) DPBA, THF, 50C, 16 hr.
2, THF, 50
C, 24 hr.
al sigmoidal model (n = 6) (Fii).
e-sample t test), n = 4. ns, not significant.
whereas NBC11 is chelated to B through O/N chelation of the
ketone C=O and enamine NH (Figure 4B). Thus full substitution
of the primary amide (NBC6) to an N,N-dimethyl tertiary amide
(NBC11) has induced a change in B chelation, which could
explain the large difference in observed bioactivity between
these two oxazaborines (Figure 3B).
Computational modeling was applied to further investigate
the impact of the shape and electronic properties of the NBCs
on the bioactivity and observed SAR. All of the compounds
were energy optimized at the M06-L/6-31G* level of quantum
mechanics (Zhao and Truhlar, 2006). Consistent with the X-ray
crystal structures, computational modeling predicted that the
rings in the oxazaborines adopted boat-envelope conformations
(NBC6 [Figure 4A] and NBC11 [Figure 4B]). Indeed, the agree-
ment in ring pucker of the 6-membered ring between calcula-
tion and the X-ray structures was very good: for NBC6, the
mean unsigned ring pucker torsion <n> differs by 2.1 while for
NBC11 the difference is 5.7 (Table S1). There was good agree-
ment with experiment in the use of M06 functionals to model
coordinate B-N bond lengths and bond enthalpies of methyl-
substituted aminoboranes (Janesko, 2010). For NBC6 and
NBC11, the average experimental pucker <n> was 25.4 and
21.1, respectively (Table S1). This indicates significant deviation
from planarity; the greatest pucker for both rings centered
around the B atom,with a n5 angle of45.4 and37.3, respec-
tively (Table S1). Computed bond distances within the ring also
reproduce the experiment well, with a maximum deviation from
the crystallographic values of 0.02 A˚ for NBC6 and 0.01 A˚ for
NBC11 (Table S1). The largest difference in ring bond distance
between NBC6 and NBC11 is found for the C5-C6 bond, with
predicted and experimental distances agreeing on a 0.05-A˚
larger bond distance in NBC6 (Table S1). In contrast, energy
optimization of the NBC diazaborine compounds, containing
the N-B-N motif, predict at the M06-L/6-31G* level a planar
diazaborine ring (e.g., NBC27 [18], and NBC30 [19], Figure 4D).
The planarity is reflected by a mean unsigned pucker angle
<n> of 3.3 and 11.4 for NBC27 and NBC30, respectively
(Table S1), distinctly lower than the values for NBC oxaborines,
which exceed 20. Furthermore, the N-B-N angle in these com-
pounds are 112.5 and 111.2 for NBC27 and NBC30, respec-
tively, compared with O-B-N angles of 102.6 and 104.0 in the
NBC6 and NBC11 X-ray structures (q, Table S1). These geo-
metric features reflect the more aromatic character of the diaza-
borine systems.
Further insight into electronic distribution was obtained from
Mulliken population analysis: firstly we note that the B atom is
predicted to possess a positive partial charge in all of the NBC
compounds analyzed (Figures 4C and 4D; Table S1). The charge
on the B atom is on average 0.59 e for the 24 O-B-N compounds,
0.60 e for 3 O-B-O compounds, and somewhat less for the 3
N-B-N compounds, with an average value of 0.51 e. This reflects
the low Pauling electronegativity of the B atom, reported as 2.04
compared with values of 3.04 for N and 3.44 for O (Allen, 1989).
Thus, although we traditionally represent 4-coordinate B atoms
with a formal negative charge (e.g., Figure 3), quantum chemical
analysis predicts that the B atom in the heterocycle of these
NBC compounds possesses a partial positive charge. The
magnitude of the partial atomic charge on carbon C6, q(C6) is
higher for NBC6 and NBC19 (>0.6 e) compared with less activecompounds NBC11, NBC27, and NBC30 (<0.5 e, Table S1).
For oxazaborines, a higher value of q(C6) appears to be due to
the presence of an amido substituent at C6. The correlation of
q(C6) and observed activity of the compounds is somewhat
modest, with a correlation coefficient r2 of 0.5 (a similar corre-
lation is found for the C5-C6 bond distance); this reflects the
influence of other factors, in particular steric constraints on sub-
stituents. 3D-QSAR was performed using the topomer compar-
ative molecular field analysis (CoMFA) method (Cramer, 2003),
based on oxazaborines NBC1–6, 8, 11–20, 22–26, and 28–29
compounds (r2 of 0.71). Again, our analysis highlights the
steric volume required for activity at position 6 (Figure 4E), and
indicates the complementarity of the cyclohexyl substituent
of NBC19 compared with the weakly active NBC20 compound,
which presents a bulkier pyrene group at C6 (Figure 4E). In
summary, the density functional calculations agree well with
crystallographically determined structures and indicate a shape
and electronic character of the oxazaborine ring that is distinct
from the planar, aromatic diazaborine ring, suggesting that these
features are responsible for the activity of the oxazaborines.
Within the oxazaborine series, there is evidence of a specific
steric constraint on substituents at position 6 of the ring.
Mechanism of Action
We measured the effects of 2APB, BC7, BC23, and NBC6 on
ASC speck formation following ATP stimulation. Immortalized
(i)BMDMs transduced with a lentiviral vector to express ASC-
mCherry (Daniels et al., 2016) were treated with LPS and then
stimulated with ATP for between 30 and 45 min with ASC speck
formation measured as described previously (Daniels et al.,
2016). 2APB was an effective inhibitor of ASC speck formation,
as were BC23 and NBC6 (Figure 5A). Additionally, we showed
that 2APB is not a direct inhibitor of caspase-1. Recombinant
caspase-1 was incubated with vehicle, YVAD, or 2APB before
addition of the fluorogenic substrate Z-YVAD-AFC. Caspase-1
activity was measured 2 hr later. Under these conditions 2APB
had no effect on caspase-1 activity while YVAD caused com-
plete inhibition (Figure 5Bi). We also used a hypotonic THP-1
cell lysate assay to measure the effects of 2APB on caspase-1
activity. 2APB was added to the cells just prior to, or following,
lysis in hypotonic buffer. The lysate was incubated with the
caspase substrate Z-YVAD-AFC, which in addition to caspase-1
would also be cleaved by caspase-4 and -5, and caspase ac-
tivity was measured 2 hr later. 2APB had no effect on caspase-1
activity under these conditions, whereas caspase-1 activity was
completely inhibited by YVAD or high K+ concentration (Fig-
ure 5Bii). An important step in the activation of NLRP3 is K+ efflux
from the cell (Munoz-Planillo et al., 2013). It was reported
recently that 2APB does not inhibit K+ efflux (Katsnelson et al.,
2015), so the effect of 2APB must be downstream of K+ efflux
and before caspase-1 activity. Recently additional mechanisms
of NLRP3 activation have been reported, including by the small
molecule imiquimod, which is suggested to be independent of
K+ efflux (Gross et al., 2016). In LPS-primed primary BMDMs,
NBC6 also inhibited imiquimod-induced IL-1b release (Fig-
ure 5C). We also tested whether NBC6 could inhibit IL-1b
secretion through the non-canonical NLRP3 pathway. Priming
with the TLR2 agonist Pam3CSK4 followed by LPS transfec-
tion stimulates the activation of NLRP3 via the non-canonicalCell Chemical Biology 24, 1321–1335, November 16, 2017 1327
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Figure 5. NBCs Are Effective NLRP3 Inflammasome Inhibitors
(A) The effects of 2APB, BC7, BC23, and NBC6 on ASC speck formation following ATP stimulation were measured. iBMDMs stably expressing ASC protein
conjugated to mCherry were primed with LPS (1 mgmL1, 2 hr), then pre-treated with selected drug (indicated concentration, 15 min) before stimulation with ATP
(legend continued on next page)
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caspase-11-dependent pathway (Kayagaki et al., 2013). Primary
BMDMs were primed with Pam3CSK4 followed by transfection
with LPS (Kayagaki et al., 2013). Neither NBC6 nor MCC950
inhibited the release of IL-1a (Figure 5Dii), which occurs due
to caspase-11-dependent pyroptosis independently of NLRP3
(Kayagaki et al., 2011). However, NBC6 and, as previously re-
ported (Coll et al., 2015), MCC950 did inhibit the release of
IL-1b (Figure 5Di). These data suggest that NBC6 can also inhibit
NLRP3 via the non-canonical pathway. To determine whether
the NBCs were selective inhibitors of NLRP3-dependent IL-1b
release, we tested their effects against other well-characterized
inflammasomes in primary wild-type (WT) and NLRP3 knockout
(KO) BMDMs. LPS-primed WT BMDMs were treated with ATP
in the absence and presence of NBC6 (10 and 30 mM), the es-
tablished NLRP3 inhibitor MCC950 (Coll et al., 2015) (30 mM),
and the caspase-1 inhibitor YVAD (100 mM). Under these condi-
tions, all inhibitors inhibited the release of IL-1b (Figure 5E). In
NLRP3 KO BMDMs a similar format was followed except that
NLRC4 inflammasome activation was induced by transfection
of Salmonella typhimurium flagellin, whereby this time 10 and
30 mM NBC6 and 30 mM MCC950 had no effect (Figure 5E).
The same format was followed for AIM2 inflammasome activa-
tion whereby LPS-primed NLRP3 KO BMDMs were transfected
with poly(dA:dT). Again 10 mMNBC6 and 30 mMMCC950 had no
effect and YVAD inhibited IL-1b release, as did 30 mM NBC6
(Figure 5E). These data suggest that NBC6 selectively inhibits
NLRP3 at low doses but may also be effective against other in-
flammasomes at higher doses. To further establish that NBC6
inhibits NLRP3 across cell types, neutrophils were isolated
from WT and NLRP3 KO murine bone marrow and primed with
LPS followed by nigericin treatment in the presence or absence
of 10 mM NBC6. From this we observed complete inhibition of
NLRP3-dependent IL-1b release from NBC6-treated neutrophils
(Figure 5F).
We next compared the toxicity of NBC6 with that of MCC950
in kidney (HEK293) and liver (HepG2) cell lines. Neither drug
showed any toxicity up to 24 hr of incubation (Figure 6A). To
further refine the mechanism of action of NBCs on NLRP3,(5 mM, 30–45 min) under live microscopy. Formation of ASC specks (examples in
presented as mean percentage of specks counted versus vehicle + SEM (n = 5–
(Holm-Sidak corrected one-sample t test, n = 5–6). Scale bars, 20 mm.
(B) Recombinant caspase-1 (10 UmL1) was incubated with 0.5%DMSO, YVAD (
AFC. Caspase-1 activity was measured 2 hr later (Bi) (***p < 0.001, significant diffe
Hypotonic THP-1 cell lysate assay was also used to measure the effects of 2AP
following, lysis in hypotonic buffer. The lysate was incubated with Z-YVAD-AFC a
were included as controls (Bii) (***p < 0.001, significant difference from relevant
(C) LPS-primed (1 mg mL1, 4 hr) mouse primary BMDMs were treated with NBC
NLRP3 activator imiquimod (70 mM) or DMSO control. Imiquimod significantly
(#p < 0.05, Holm-Sidak corrected post hoc comparison, n = 4).
(D) Mouse primary BMDMs were primed with Pam3CSK4 (100 mg mL1, 4 hr) fo
intracellular LPS (2 mgmL1, transfected with Lipofectamine 3000, 24 hr) or Lipofe
versus Lipofectamine-alone control; ##p < 0.01, significant inhibition of IL-1b rele
(E) Mouse primary BMDMs were primed with LPS (1 mg mL1, 4 hr) followed by 1
treated with canonical NLRP3 activator ATP (5 mM, 1 hr), NLRC4 activator (fla
(poly(dA:dT), 667 ng mL1, transfected with Lipofectamine 3000) (*p < 0.05, **p <
post hoc comparison, n = 3).
(F) Mouse primary bone marrow neutrophils fromWT and NLRP3 KOmice (n = 4)
prior to the addition of nigericin (10 mM), which significantly induced IL-1b release (
corrected post hoc comparison).
Data are presented as the mean + SEM.we sought to determine the reversibility of NBC inhibition of
NLRP3-dependent IL-1b release. iBMDMs were primed with
LPS and then incubated with the reversible caspase-1 inhibitor
YVAD, the irreversible NLRP3 inhibitor 3,4-methylenedioxy-
b-nitrostyrene (MNS; He et al., 2014), NBC6, BC23 (from the
BC series), and 2APB for 15 min before 3 washes over
15 min to remove unbound drug. Cells were then stimulated
with ATP (5 mM) to activate NLRP3-dependent IL-1b release.
As expected, YVAD washed out and MNS did not. The effects
of NBC6 and BC23 resembled that of MNS and were irrevers-
ible over the time course of the experiment (Figure 6B). Inter-
estingly 2APB was reversible (Figure 6B). To test whether the
NBC molecules could inhibit NLRP3-dependent inflamma-
tion in vivo, we used a previously reported model of peritonitis
(Coll et al., 2015). Previously, mice injected intraperitoneally
with LPS showed increased IL-1b in the lavage fluid that was
inhibited by the NLRP3 inhibitor MCC950 (Coll et al., 2015).
Thus we injected WT and NLRP3 KO mice with LPS. Separate
groups of animals receiving LPS were also given a dose of
MCC950 or NBC13, chosen because it had similar potency
to NBC6 at inhibiting IL-1b release and was soluble in corn
oil, which was used to deliver the drug. LPS induced an in-
crease in IL-1b in the lavage and plasma in WT mice but not
NLRP3 KO mice, supporting the NLRP3 dependence of this
response (Figure 6C). MCC950, as expected, also inhibited
LPS-induced IL-1b production in the peritoneum, as did
NBC13, suggesting that NBCs are effective NLRP3 inhibitors
in vivo (Figure 6Ci). LPS also caused an increase in plasma
IL-1b, which was also absent in NLRP3 KO mice and was
completely inhibited by MCC950 (Figure 6Cii). NBC13 signifi-
cantly inhibited LPS-induced plasma increases in IL-1b but
was not quite as effective as MCC950, possibly due to
reduced exposure or potency (Figure 6Cii). Both NBC13 and
MCC950 significantly inhibited the production of the related
cytokine IL-1a in the plasma (Figure 6Ciii). Together, these
data show that the NBCs are effective inhibitors of the
NLRP3 inflammasome and can also target NLRP3-dependent
inflammation in vivo.dicated by white arrows, Ai [no drug], Aii [plus NBC6]) were quantified (Aiii) and
6). **p < 0.01, ***p < 0.001, significant difference from 100% speck formation
100 mM), or 2APB (75 mM) before addition of the fluorogenic substrate Z-YVAD-
rence from vehicle control, Holm-Sidak corrected post hoc comparison, n = 4).
B on caspase-1 activity. 2APB (75 mM) was added to the cells just prior to, or
nd caspase-1 activity measured 2 hr later (Bii). YVAD or high K+ concentration
lysis vehicle control, Holm-Sidak corrected post hoc comparison, n = 4).
6 (10 mM) or vehicle (DMSO) 15 min prior to 1 hr treatment with small-molecule
induced IL-1b release (**p < 0.01) and this was inhibited by NBC6 treatment
llowed by 15 min NBC6 (1 mM), MCC950 (1 mM), or vehicle, then treated with
ctamine alone (**p < 0.01, significant induction of IL-1b [Di] or IL-1a [Dii] release
ase; Holm-Sidak corrected post hoc comparison, n = 4).
5 min NBC6 (10 and 30 mM), MCC950 (30 mM), YVAD (100 mM), or vehicle, then
gellin, 667 ng mL1, transfected with Lipofectamine 3000), or AIM2 activator
0.01, ***p < 0.001, significant inhibition of IL-1b release, Holm-Sidak corrected
were primed with LPS (1 mg mL1, 2 hr), then NBC6 (10 mM) was added 15 min
***p < 0.001), whichwas inhibited by NBC6 treatment (###p < 0.001, Holm-Sidak
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Figure 6. NBCs Are Effective against NLRP3 In Vivo
(A) HEK293 or HepG2 cells were treated with NBC6 (10 mM), MCC950 (10 mM), or DMSO for 4 hr, 8 hr, and 24 hr. Cell death was measured by lactate
dehydrogenase release and expressed as percentage lysis control. No significant effects were observed (two-way repeated-measures ANOVA).
(B) LPS-primed (1 mg mL1, 2 hr) iBMDMs were pre-treated with drugs (BC23, NBC6, 30 mM; MNS, 100 mM; YVAD, 100 mM; 2APB, 75 mM) or vehicle (DMSO) in
serum-free media for 15 min and washed 3 times, before inflammasome activation was initiated by adding ATP (5 mM) for 1 hr. IL-1b release was measured by
ELISA (*p < 0.05, **p < 0.01, ***p < 0.001, significant inhibition of IL-1b release compared with vehicle-ATP control; #p < 0.05, ###p < 0.001, significant effect of
washing compared with no-wash drug-ATP control, Holm-Sidak corrected post hoc comparison, n = 5–6).
(C) C57BL/6 andNLRP3KOmice (n = 6) were injected intraperitoneally with LPS (10mg kg-1, 3 hr). Separate groups ofWT animals receiving LPSwere also given a
50 mg kg1 dose of MCC950 or NBC13. IL-1b in peritoneal lavage (Ci) and plasma (Cii) was measured by ELISA. IL-1a in plasma was measured by ELISA (Ciii).
***p < 0.001, significant difference from saline vehicle control; ##p < 0.01, ###p < 0.001, significant difference from LPS vehicle group (Holm-Sidak corrected post
hoc comparison).
Data are presented as the mean + SEM.Ca2+-Independent Effects of the NBCs
We recently reported that the fenamates were effective inhibitors
of the NLRP3 inflammasome due to inhibition of Cl efflux1330 Cell Chemical Biology 24, 1321–1335, November 16, 2017through the volume-regulated anion channel (VRAC) (Daniels
et al., 2016). Thus we tested the effects of BC23, BC7, and
NBC6 on VRAC. VRAC currents measured by whole-cell patch
clamp in LPS-primed iBMDMs were induced by hypotonicity.
BC7, BC23, and NBC6 had no effect on VRAC (Figure 7A). As
described above, 2APB is known to modulate Ca2+ homeosta-
sis. Thus we tested the ability of 2APB and NBC6 tomodify intra-
cellular Ca2+ in LPS-treated iBMDMs stimulated with ATP. The
cells were pre-treated with doses of the inhibitors maximal for
blocking IL-1b release (i.e., 2APB 75 mM, NBC6 30 mM). The cells
were then stimulated with 100 mMATP (submaximal for P2X7 but
saturating for other purinergic receptors) to induce increases in
[Ca2+]i, which were measured using the ratiometric Ca
2+ indica-
tor Fura-2 (Figures 7B–7D). ATP induced a transient increase in
[Ca2+]i that was inhibited by 2APB but was not blocked by
NBC6 (Figures 7B–7E), suggesting that the NBC compounds
did not affect [Ca2+]i changes dependent upon InsP3 receptor
activation. iBMDM cells were then treated with LPS and stimu-
lated with 5 mM ATP to activate the P2X7 receptor and induce
activation of NLRP3. Under these conditions there was amarked
and sustained increase in [Ca2+]i (Figures 7F and 7G). Inhibitor
(2APB 75 mM, NBC6 30 mM) applied to the cells 3 min after
ATP did not affect [Ca2+]i, again supporting that the effects of
2APB and the NBC compounds are acting independently of
effects on Ca2+ (Figures 7F and 7G). To correlate with this Ca2+
experiment, inhibitors were added to the iBMDMs following
ATP stimulation as described above and effects on IL-1b release
were measured 1 hr later by ELISA (Figures 7H and 7I). Adding
drug after stimulation of the large Ca2+ increase inhibited inflam-
masome activation and IL-1b release as effectively as the pre-in-
cubation (Figures 7H and 7I). Together, these data suggest that
the inhibitors are acting independently of any effects on Ca2+ and
that the effect on Ca2+ for the NBC compounds is not significant.
DISCUSSION
The NLRP3 inflammasome contributes to inflammatory dis-
eases and is therefore an important therapeutic target (Lamkanfi
and Dixit, 2012). Increasing recognition of the contribution of
NLRP3 to disease has led to efforts to develop small-molecule
inhibitors (Baldwin et al., 2016). Here we report the development
of a unique B-based pharmacophore that inhibits NLRP3-
dependent inflammation in both in vitro and in vivo models.
Boron is an unusual element to be present in drug leads; borte-
zomib (Velcade) is the only B-containing drug used clinically.
After establishing that B was essential for inhibition through
screening of carbon analogs, we synthesized a range of new
B-based inhibitors of NLRP3 derived from the early leads
2APB, BC7, and BC23, the most potent compound having an
IC50 value of 574 nM for the inhibition of release of IL-1b from
THP-1 monocytes.
During the preparation of the oxazaborines, for the synthesis
of acetylated enaminone intermediates, we found that the
choice of the metal catalyst was critical; Zn(acac)2 was
amenable with good electrophiles (e.g., trichloroacetonitrile
and benzonitrile); however, the stronger catalyst SnCl4 was
required with non-electrophilic, weakly activating nitriles (e.g.,
acetonitrile and tert-butyl acetonitrile). The oxazaborines syn-
thesized herein can be handled easily at room temperature, in
contrast to the facile hydrolysis observed for 2APB (Hofer
et al., 2013). Molecular modeling calculations agreed well with
the X-ray crystal structures of NBC6/11, demonstrating therobustness of predictions using quantum mechanics. This is
the first time that biological screening of oxaza-, dioxa-, and
diazaborines has been reported. The SAR of the 31 NBC mole-
cules revealed interesting key features required for bioactivity,
with the oxazaborine ring and CCl3 group being essential phar-
macophores for NLRP3 inflammasome inhibition.
NLRP3 is composed of three domains: an N-terminal pyrin
domain for homotypic interaction with the pyrin domain of the
adaptor ASC, a central NACHT domain that binds nucleotides,
and a C-terminal leucine-rich repeat domain that senses the
PAMPs or DAMPs. The mechanisms regulating the activation
of NLRP3 are currently the focus of a major research effort in
the field and are still being elucidated. There is very limited
evidence for an interaction between PAMP/DAMP and NLRP3;
instead these activating stimuli activate a common pathway
dependent upon K+ efflux (Munoz-Planillo et al., 2013). Recently,
the protein NEK7 has been identified as an interacting partner of
NLRP3 required for its activation (Schmid-Burgk et al., 2016; Shi
et al., 2016), and this interaction is also downstream of K+ efflux
(He et al., 2016). In addition, ubiquitination and deubiquitination
are also becoming established as essential steps (Lopez-Caste-
jon et al., 2013; Juliana et al., 2012; Py et al., 2013). There has
also been substantial literature to support an involvement of
Ca2+ in inflammasome activation. Many of the studies reporting
Ca2+ dependence of NLRP3 activation have been based on, or
involved the use of 2APB as an inhibitor of Ca2+ signaling (Lee
et al., 2012; Murakami et al., 2012; Compan et al., 2012; Rossol
et al., 2012), or intracellular Ca2+ chelators such as BAPTA-AM
(Brough et al., 2003). However, there is now evidence that
both of these experimental manipulations may inhibit the inflam-
masome independently of effects on Ca2+ (Katsnelson et al.,
2015). Further evidence for an effect independent of Ca2+ is pro-
vided in Figure 1, and is related to the work of Dobrydneva and
Blackmore (2001) on store-operated Ca2+ entry. While they
showed that DPBA inhibits Ca2+ entry (and IL-1b release pre-
sented here), DPTTF, which had no effect on IL-1b release in
our study, inhibited Ca2+ entry as effectively as DPBA (Dobryd-
neva and Blackmore, 2001). Such data further support that the
effects of 2APB on IL-1b processing and release are indepen-
dent of Ca2+. Here we also show that while 2APB effectively
inhibits increased [Ca2+]i in response to 100 mM ATP, NBC6
does not, even at concentrations supra-maximal for the inhibi-
tion of IL-1b secretion (Figure 7). Furthermore, addition of
2APB, or NBC6 after the addition of 5 mM ATP, an NLRP3-acti-
vating stimulus, did not modify [Ca2+]i dynamics, but did still
inhibit IL-1b secretion following this protocol (Figure 7). These
data suggest strongly that the effects of 2APB on IL-1b release
are independent of Ca2+, and that we have deselected this
property in our NBC molecules. This effectively provides a new
and unique chemical scaffold for the development of NLRP3-in-
hibiting drugs that do not have the potentially harmful off-target
effects on Ca2+ homeostasis.
SIGNIFICANCE
Excellent evidence now points toward NLRP3 as an impor-
tant therapeutic target for multiple major diseases (Guo
et al., 2015). There are no drugs available clinically that
specifically target NLRP3, although we (Daniels et al., 2016)Cell Chemical Biology 24, 1321–1335, November 16, 2017 1331
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Figure 7. Ca2+-Independent Effects of the NBCs
(A) To induce volume-regulated Cl currents (VRAC), LPS-primed (1 mg mL1, 2 hr) iBMDMs were superfused with hypotonic solution. Representative current
traces are shown, which have been measured in the absence (VRAC) or presence of 30 mM NBC6 (Ai), 30 mM BC7 (Aii), or 30 mM BC23 (Aiii).
(B–E) LPS-primed (1 mgmL1, 2 hr) iBMDMswere kept untreated or were pre-treated for 2 min with 75 mM2APB or 30 mMNBC6. Subsequently, 100 mMATPwas
added to the bath solution. (B–D) Representative Ca2+ traces of ATP-stimulated cells in the absence (B, n = 12) or presence of 75 mM 2APB (C, n = 14), or 30 mM
NBC6 (D, n = 12). (E) Mean peak Ca2+ concentrations determined in cells treated with ATP alone (ATP) or with ATP in the presence of inhibitors. ns, no significant
difference; ***p < 0.001, significant difference from Ca2+ signals of ATP-stimulated cells determined in the absence of inhibitors (Holm-Sidak corrected one-
sample t test).
(F andG) LPS-primed iBMDMswere also stimulated with 5mMATP. Following development of sustainedCa2+ increases, 75 mM2APBor 30 mMNBC6was added
to the ATP-containing solution. Images show representative examples of Ca2+ responses following treatment with ATP and the addition of 2APB (n = 12, F) or the
addition of NBC6 (n = 12, G).
(H and I) LPS-primed iBMDMswere treated with concentrations of the inhibitors maximal for blocking IL-1b release (i.e., 2APB = 75 mM,NBC6 = 30 mM). Inhibitors
were added to the iBMDMs 5 min before or 5 min after the addition of ATP (5 mM, 1 hr) (H) with IL-1b release measured by ELISA (I). ***p < 0.001, significant
difference from corresponding vehicle control; ns, no significant effect of ATP administration time.
Data are presented as representative traces from calcium imaging experiments (B–D, F, and G), mean + SEM peak Ca2+ concentrations versus treatment with
ATP alone (E), or mean + SEM IL-1b release as detected by ELISA (I).
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and others (Fowler et al., 2014) have shown that some exist-
ing drugs may be repurposed. There is, however, a need for
new inhibitors. MCC950 (formerly CRID3 or CP-456,773) is
being developed as a potent and selective inhibitor of
NLRP3 (Coll et al., 2015). Here we report a new class of mol-
ecules based on the oxazaborine ring that will further accel-
erate the development of NLRP3 inhibitors for use in disease
and in generating new fundamental insights.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
Primary peritoneal macrophages were prepared as described previously (Le Feuvre et al., 2002). Briefly, peritoneums of male and
female C57BL/6 mice (Charles River) were lavaged with 8 ml RPMI 1640 media and cells in the exudate cultured at a density of
13 106 cellsml-1 in RPMImedia supplementedwith 10% fetal bovine serum (FBS), 100 Uml-1 penicillin and 100 mgml-1 streptomycin
(PenStrep). Primary bone marrow-derived macrophages (BMDMs) and primary bone marrow neutrophils were prepared by flushing
femurs ofmale and femalewild-typeC57BL/6 or NLRP3KOmice. Red cells were then lysed. BMDMswere generated by culturing the
resulting bone marrow cells in 70% DMEM (containing 10% FBS, PenStrep) supplemented with 30% L929 mouse fibroblast-condi-
tioned media for 7-10 days. Before experiments, cells were seeded overnight at 1 x 106 ml1 in 96-well plates. Neutrophils were iso-
lated by density centrifugation of the extracted bone marrow cells in a 64% isotonic Percoll (Sigma-Aldrich) at 1,000xg for 30 min at
4C. The pellet was then resuspended in RPMI (containing 10% FBS, PenStrep), counted, centrifuged again (2,000xg, 5 min), resus-
pended at 1 x 106ml-1, plated in 96-well plates and experimented on immediately. Purity (>90%) and viability (>95%)were determined
by Diff-Quik staining (Cools-Lartigue et al., 2013). THP-1 peripheral blood monocyte-like cells were cultured in RPMI medium sup-
plemented with 10% FBS, PenStrep, 20 mM L-Glutamine and 55 mM 2-mercaptoethanol. On the day of experiments, cells were
seeded overnight at 1 x 106 ml-1 in 96-well plates. Immortalized murine bone marrow-derived macrophages (iBMDMs) (Hornung
et al., 2008) and iBMDMs stably expressing ASC conjugated to mCherry protein (Daniels et al., 2016) were cultured in DMEM, 10%
FBS, PenStrep. HEK293T kidney cells and HepG2 liver cells were cultured in DMEM, 10% FBS, PenStrep.
In Vivo Peritoneal Inflammation Model
Animals were maintained under standard laboratory conditions: ambient temperatures of 21C (± 2C), humidity of 40–50%, 12 h
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allocations were randomly allocated using True Random Generator software. All animal experiments were carried out in accor-
dance with the United Kingdom Animals (Scientific Procedures) Act 1986 and approved by the Home Office and the local Animal
Ethical Review Group, University of Manchester. Male WT C57BL/6 and strain matched NLRP3 KO mice (30 - 35g) were co-
administered intraperitoneally (i.p.) with NBC13 (50 mg kg-1), MCC950 (50 mg kg-1) or vehicle (corn oil)), and 10 mg kg-1 LPS
(from Escherichia coli 0127:B8) or saline control (n=6 per group). Three hours following injection the mice were anesthetized with
3-5% isoflurane, their peritoneums were lavaged with 3 ml of RPMI media and plasma taken by cardiac puncture. Levels of IL-1b
in the plasma and lavage and IL-1a in the plasma were analysed by ELISA (DuoSet, R&D systems).
METHOD DETAILS
ASC Speck Imaging
Live imaging of ASC speck formation was performed using iBMDMs transfected to stably express ASC conjugated to mCherry pro-
tein (Daniels et al., 2016). Stably transduced cells were plated overnight at 5x105 cells ml-1. The following day, cells were primed with
LPS (1 mg ml-1, 2 h). 1 h into priming, Hoechst 33342 (2 mg ml-1, Immunochemistry) was added to aid identification of the cells.
Following priming, media was changed to DMEM containing 25 mMHEPES pH 7.4 and cells transferred to a BD Pathway Bioimager
855 (BD Biosciences) and imaged at 37C as described previously (Daniels et al., 2016). Cells were pre-treated with 2APB, BC7,
BC23, NBC6, or vehicle for 15 min before imaging.
Caspase-1 Assays
The caspase-1 activity of THP-1 cells was determined with the fluorogenic substrate Z-YVAD-AFC (caspase-1 substrate VI, Calbio-
chem) as previously described (Lopez-Castejon et al., 2013). Briefly, cells were lysed in hypotonic cell lysis buffer (25 mM HEPES,
5 mM EGTA, 5 mM dithiothreitol (DTT), pH 7.5) on ice for 5–10 min and centrifuged to remove the insoluble fraction (12,5003g,
10min). THP-1 lysates (50 ml) or recombinant caspase-1 (10 Uml-1) was incubated with 50 mMYVAD-AFC and 50 ml of reaction buffer
(0.2% CHAPS, 0.2 M HEPES, 20% sucrose, 29 mMDTT, pH 7.5) for 2 h. After incubation, the fluorescence of the AFC released from
the Z-YVAD-AFC substrate was measured by an increase in fluorescence (excitation 335 nm, emission 460 nm).
Inflammasome Activation Assays
Peritoneal macrophages were primed with LPS (1 mgml-1, 2 h) before incubation with inhibitors in serum free media (15min) followed
by stimulation with NLRP3 activators ATP (5 mM, 20 min), mono-sodium urate crystals (MSU, 250 mg ml-1, 1 h), calcium pyrophos-
phate dihydrate crystals (CPPD, 250 mg ml-1, 1 h), Aluminium hydroxide crystals (Alum, 250 mg ml-1, 1 h), nigericin (20 mM, 15 min), or
sphingosine (20 mM, 1 h). THP-1 cells were primed with LPS (1 mg ml-1, 4 h) before incubation with inhibitors or vehicle (15 min) in
serum-free media followed by stimulation with nigericin (10 mM, 1 h), or ATP (5 mM, 1 h). For AIM2/NLRC4 inflammasome activation
primary BMDMs were primed with LPS (1 mg ml-1, 4 h). Subsequent to LPS priming, cells were pre-treated with drugs or vehicle
(DMSO) in serum-free media for 15 min then stimulated with ATP (5 mM, 1 h), poly(deoxyadenylic-thymidylic) (polydA:dT) acid
sodium salt transfected with Lipofectamine 3000 (667 ng ml-1, 4 h) or flagellin from S. typhimurium (667 ng ml-1, 4 h). For K+
efflux-independent NLRP3 activation BMDMs were primed with LPS as above. Subsequent to LPS priming, cells were pre-treated
with drugs or vehicle (DMSO, 15min) in PBS then stimulatedwith imiquimod (10 mM, 4 h). For non-canonical inflammasome activation
cells were primed with Pam3CSK4 (100 ng ml-1, 4 h). Subsequent to priming, cells were pre-treated with drugs or vehicle (DMSO,
15 min) in serum-free media then stimulated with LPS transfected with Lipofectamine 3000 (2 mg ml-1, 24 h). Neutrophils were
primed with LPS (1 mg ml-1, 2 h) in RPMI (containing 10% FBS, PenStrep), drug or vehicle (DMSO) was added 15 min prior to the
stimulation with nigericin or vehicle (DMSO) for 1 h. Supernatants were removed and analysed for IL-1b or IL-1a content by ELISA
(DuoSet, R&D systems) according to manufacturer’s instructions.
Washout Experiments
iBMDMs were seeded overnight at 7.5 x 105 ml-1 in 24-well plates and primed with LPS (1 mg ml-1, 2 h). Subsequent to LPS priming,
cells were pre-treated with drugs or vehicle (DMSO, 15 min) in serum-free media and washed 3 times, before inflammasome activa-
tion was initiated by adding ATP (5 mM, 1 h).
Cell Death Experiments
HEK293T kidney cells and HepG2 liver cells were treated with drug or vehicle (DMSO) for 4, 8 and 24 h in DMEM, 1% FBS, PenStrep.
Following treatment, cell death wasmeasured by assessing lactate dehydrogenase release using the CytoTox 96Non-Radioactive
Cytotoxicity Assay (Promega) according to manufacturer’s instructions.
Chemistry Synthesis
Synthesis, purification and characterisation of NBC molecules are outlined in Methods S1 (Ibrahim et al., 1985; Coenen et al., 1965;
Hosoya et al., 2006; Vasil’ev et al., 1994; Sridharan et al., 2010; Clemens and Hyatt, 1985). All chemicals, solvents and deuterated
solvents were purchased from Sigma-Aldrich, Alfa-Aesar or Fisher Scientific. 1H, 13C and 11B{1H} NMR spectra were recorded on a
Bruker Avance 400 or 300 MHz spectrometer. Chemical shifts (d) are defined in parts per million (ppm). 1H NMR spectra were refer-
enced to tetramethylsilane (TMS, d=0.0 ppm) or residual undeuterated solvent (CDCl3, d=7.26 ppm; DMSO-d6, d=2.50 ppm).e3 Cell Chemical Biology 24, 1321–1335.e1–e5, November 16, 2017
13C NMR spectra were referenced to residual undeuterated solvent as an internal reference. 11B{1H}NMR chemical shifts were refer-
enced to external reference BF3.OEt2 (d=0.0 ppm). ESI and APCI mass spectrometry was carried out on aWaters Acquity UPLC sys-
tem connected to a Waters SQD2 mass spectrometer. Accurate mass determination was carried out on a Thermo Exactive Plus
EMR Orbitrap LC-MS system. Molecular ion peaks are defined as mass/charge (m/z) ratios. Infrared spectroscopy was recorded
on a JASCO FT/IR-4100 spectrophotometer using the Spectra Manager II (JASCO) software package. Microwave irradiation was
carried out on a Biotage Initiator Classic microwave using 2-5 ml Biotage glass vials. Analytical thin-layer chromatography
(TLC) was performed using silica gel 60 on aluminium sheets coated with F254 indicator. All spots were visualised with KMnO4 or
ultraviolet light using a MV Mineralight lamp (254/365) UVGL-58. Flash column chromatography was performed using silica gel
with particle size 40-63 mm. Evaporation of solvents was conducted on a Buchi Rotavapor R-200.
X-ray Crystallography
X-ray diffraction data were collected at 100 K on the specimen crystals of NBC6 and NBC11 at the National Crystallography Service,
Southampton, UK, with MoKa radiation produced by a rotating anode generator. The structures were solved by direct methods with
SHELXS and refined with SHELXL, implemented in the WinGX package (Farrugia, 2012), by the full-matrix least-squares technique
with anisotropic displacement parameters for the non-hydrogen atoms. Hydrogen atoms attached to carbon were placed in calcu-
lated positions and assumed to ride on their attached atom, methyl groups being allowed to rotate. The C12 methyl group of NBC11
showed signs of disorder in a difference electron density map and therefore was assigned two sets of sites rotated by 60 from one
another with occupancy factors that refined to 0.59(2) : 0.41(2). Positions and isotropic displacement parameters for hydrogen atoms
attached to nitrogen atoms were refined freely. Final discrepancy indices R(obs) and wR2 (all data) were 0.0408, 0.1120 for NBC6
and 0.0283, 0.0801 for NBC11. The highest peaks and deepest holes in a difference electron density map were 0.54, -0.36 and
0.39, -0.25 e A˚-3 respectively. Cambridge Crystallographic Data Centre CCDC 1563191 (NBC6) and CCDC 1563192 (NBC11) contain
the supplementary crystallographic data.
Chemistry Computational/Modelling
Initial 3D molecular structures of boron-containing compounds were constructed and then energy minimised using the Tripos force
field in SYBYL-X. These geometries were subsequently optimised quantum mechanically with the semi-local M06-L density func-
tional (Zhao and Truhlar, 2006) and the 6-31G* basis set, using the Gaussian 09 electronic structure package (Frisch et al., 2009).
These geometries were used as input for structure-activity analysis and for virtual screening. For the latter, the ZINC subset leadsNow
was employed, containing 1,943,551 molecules (4/20/12 update). Prior to shape-based screening, multiple conformations of each
compound were generated via Omega (Hawkins et al., 2010). Shape-based screening was performed using ROCS (Grant et al.,
1996) with Tanimoto scoring via the ShapeTanimoto and ColorTanimoto functions as implemented in OpenEye (Hawkins et al.,
2007). Topomer CoMFA (Cramer, 2003) was performed using the Sybyl software package, based on NBC1-6, 8, 11-20, 22-26
and 28-29, with R-groups defined at positions 4, 5 and 6 of the oxazaborine ring.
cLogP and cLogS calculations were performed for BC7, BC23, NBC1-31 and NBC-EPPS using OSIRIS DataWarrior (version
4.5.2)(Sander et al., 2015).
Fluorescence Imaging
One day before experiments, 105 iBMDMs were seeded on glass coverslips in 24-well plates. For Ca2+ imaging experiments cells
were transferred to the following solution containing (in mM): NaCl, 130; KCl, 5; HEPES, 10; D-glucose, 10; CaCl2, 2; MgCl2,
1 (pH 7.4) and were loaded with 3 mM fura-2-acetoxymethylester (Fura-2-AM, Molecular Probes, Eugene, USA) for 30 min at RT
(20-23C). After washing, coverslips were mounted in a chamber on an inverted Olympus IX50 microscope equipped with a water
immersion objective 40x UApo/340 (Olympus Optical Co. GmbH, Hamburg, Germany). The fluorescence imaging system consisted
of a Polychrome V monochromator, a Hamamatsu Orca 03G camera and the Windows 7 based Live Acquisition software (Till
Photonics, M€unchen, Germany). Cells were exposed to light of 340±5 and 380±5 nm wavelength every 10 or 20 s in experiments
using 100 mM or 5 mM ATP, respectively. Emission light was passed through a 400 nm dichroic mirror and a 420 nm long pass emis-
sion filter (both Olympus, Germany) prior to acquisition. Cells were primed with LPS (1 mg ml-1, 4 h) and incubated with drug (2APB
(75 mM), BC7, BC23, NBC6 (all 30 mM)) or vehicle, pre- (2 min) or post- (3 min) ATP stimulation. Data are presented as the ratio of the
two background corrected fluorescence intensities. To enable fast drug application, cells were superfused using a four-barrel micro-
perfusion pipette positioned in close proximity to the viewing field.
Electrophysiological Recordings
One day before experiments, 105 iBMDMs were seeded on glass coverslips in 24-well plates. Membrane currents were measured
using the whole-cell configuration of the patch-clamp technique. An EPC 10 patch-clamp amplifier (HEKA, Lambrecht/Pfalz, Ger-
many) was interfaced to a computer for pulse application and data recording using the program PatchMaster (HEKA). Patch elec-
trodes of 3-5MUwere fabricated on a two-stage puller (Narishige PC 10, Tokyo, Japan) fromborosilicate glass (Hilgenberg,Malsfeld,
Germany). For volume-regulated Cl- current (VRAC) recordings, patch electrodes were filled with the following intracellular solution I1
(in mM): N-Methyl-D-Glucamine-Chloride (NMG-Cl), 120; HEPES, 10; EGTA, 11; CaCl2, 1; MgCl2, 2; Na2ATP, 3 (pH 7.3). Cells were
kept in extracellular solution E1 containing (in mM): NMG-Cl, 50; HEPES, 10; D-glucose, 10; CaCl2, 2; MgCl2, 1; D-mannitol, 170
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(in mM): NMG-Cl, 50; HEPES, 10; D-glucose, 10; CaCl2, 2; MgCl2, 1 (130 mosmol kg
-1, pH 7.3). All recordings were done at RT
(20-23C). For solution exchange, a four-barrel microperfusion pipette was used. Cells were primed with LPS (1 mg ml-1, 4 h) and
incubated with drug (2APB (75 mM), BC7, BC23, NBC6 (all 30 mM)) or vehicle, 15 min before stimulation. Whole-cell currents were
filtered at 3 kHz and stored for subsequent analyses, which were performed using the program s (HEKA, Lambrecht/Pfalz, Germany).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean values + standard error of the mean (s.e.m). Levels of significance were p<0.05 (*), p<0.01 (**), p<0.001
(***). Statistical analyses were carried out using GraphPad Prism (version 7) or R (version 3.3.0). Percentage control data were
analysed with Holm-Sidak corrected one-sample t-tests against the value of 100%. Data with multiple groups were analysed with
a one-way ANOVA. Experiments with two independent variables were analysed using two-ANOVA. These analyses were followed
by Holm-Sidak corrected post-hoc comparisons. Homoscedasticity and normality of the residuals were evaluated with the Levene’s
test and Shapiro Wilks, respectively, and appropriate transformations or corrections were applied where necessary. Dose response
curves where fitted using non-linear least squares regression with a 3 parameter logistical sigmoidal model.
DATA AND SOFTWARE AVAILABILITY
The crystallographic data for NBC6 and NBC11 is deposited with the Cambridge Crystallographic Data Centre (CCDC) with the
deposition numbers CCDC 1563191 (NBC6) and CCDC 1563192 (NBC11).e5 Cell Chemical Biology 24, 1321–1335.e1–e5, November 16, 2017
